Dr. Jennifer Jackson, PhD and Dr. Ari Rao, MD, Ph.D provide a high-level overview of biomarker testing using liquid biopsy technology. In this video, you’ll learn key terminology, what a liquid biopsy is, how it is used in clinical practice, and its relevance to breast cancer diagnosis and care.
- 00:00 Start
- 00:50 What is Biomarker Testing?
- 0:03:08 What is circulating cell-free DNA? What is liquid biopsy?
- 0:05:14 How is liquid biopsy utilized for cancer patients?
- 0:08:41 Why and when is liquid biopsy testing recommended for breast cancer patients?
- 0:11:24 How can this test be used to identify predictive biomarkers that will help determine if you are on the right therapy or if your physician needs to treat with a new therapy?
- 0:12:47 How can this test be used to confirm response to therapy?
- 0:13:59 How might liquid biopsy be suggested by your physician outside of standard of care?
- 0:15:35 What is involved in getting a liquid biopsy?
- 0:17:39 Let’s summarize what we’ve learned today about Circulating Tumor DNA?
Ari Rao, MD, Ph.D
SVP, Chief Pathology and Lab Medicine Officer
Endowed Centennial Chair, Scott and White Clinic Pathology
Professor (Non-tenured), Pathology, Baylor College of Medicine
Section Chief, Molecular Genetics
Dr. Arundhati (Ari) Rao, MD, PhD is a practicing molecular pathologist with nearly 30 years of experience in the field. She serves as Senior Vice President for Baylor Scott & White System Laboratories, Chair of Pathology for the Scott & White Clinic Pathology Department and holds the rank of Professor at the Baylor College of Medicine, Temple campus. Dr. Rao is deeply committed to advancing patient care through the development and integration of cutting-edge diagnostic technologies that support patients throughout their healthcare journeys.
Jennifer Jackson, PhD
Director, Translational Science and Strategy
Labcorp
Jennifer B. Jackson, Ph.D., is a distinguished biotechnology leader and subject matter expert with over 20 years of oncology-focused experience. Currently serving as the Director of Translational Science and Strategy at Labcorp, she leads the scientific and medical strategy for cutting-edge liquid biopsy and tissue-based CGP assays. Dr. Jackson has a proven track record of bridging the gap between “bench and bedside,” having steered novel diagnostics through product development, clinical validation, and successful commercial launch.
A biochemist by training with a Ph.D. from Emory University, her expertise spans the clinical genomics landscape, including Molecular Residual Disease (MRD) and Multi-Cancer Early Detection (MCED). She is a recognized collaborator who has built strategic partnerships with NCI-designated cancer centers and health systems across the US and EU to improve patient access to precision medicine.
